Why Did Joby’s (JOBY) $500M Defense Bet Spook Investors?
Joby Aviation (NYSE:JOBY) said it will acquire Resonant Sciences for about $500 million, with roughly $450 million in cash and $50 million in stock, to build a defense business. The deal is expected to close in H1 2027. Joby also announced a $750 million at-the-market equity offering. JOBY shares fell about 6.5% premarket.
How this was made
The 30-second read
Why it matters
The acquisition is framed as creating a profitable defense revenue engine, but the market reaction and the simultaneous $750M at-the-market equity offering shift focus to dilution and cash runway risk.
Market read
Traders likely reprice Joby’s financing risk and runway while monitoring how quickly defense revenue can offset ongoing operating cash burn.
What to watch
The article notes the deal closes in 1H27 and folds VTOL programs into Resonant; execution on integration and customer retention could matter more than the headline cash math.
Background
Joby is an eVTOL developer still dependent on FAA type certification for commercial scaling, and it is now adding a defense technology business via Resonant Sciences.
Ticker impact
Joby Aviation agreed to acquire Resonant Sciences for about $500M, $450M cash plus $50M stock, and shares fell 6.5% premarket.
Near-term downside pressure likely persists until investors gain clarity on cash runway, financing terms, and defense integration milestones.
The article cites a $318M operating cash burn in 1H26, a $450M cash payment that reduces liquidity, and a concurrent $750M at-the-market equity offering, all of which directly worsen dilution and runway concerns.
Market effects
Highlights how eVTOL firms may pursue defense-adjacent revenue to bridge the gap to FAA certification, but financing needs can dominate near-term sentiment.
Dayton, Ohio manufacturing and testing footprint expansion could support local aerospace supply-chain activity.
Defense technology demand and radio-frequency/low-observability capabilities may attract additional capital, but the deal underscores funding sensitivity across high-burn aerospace names.
Counterpoint
Investors may be over-weighting dilution and cash runway, while the deal’s >$100M trailing revenue and positive adjusted EBITDA could stabilize fundamentals faster than the market expects.
Key entities
- companyJoby Aviation
NYSE-listed eVTOL developer announcing a $500M acquisition of Resonant Sciences and a $750M ATM equity offering.
- companyResonant Sciences
Defense technology company with >$100M trailing revenue and positive adjusted EBITDA, acquired by Joby for cash and stock.
